Pharmaceuticals News and Research

RSS

Abbott presents 48-week PROGRESS study results at 28th International AIDS Conference

Abbott today presented 48-week findings comparing an HIV regimen of its protease inhibitor (PI), Kaletra® (lopinavir/ritonavir), and Merck's integrase inhibitor, Isentress® (raltegravir), to a traditional HIV regimen of Kaletra and the nucleotide/nucleoside reverse transcriptase inhibitors (NRTIs) in Truvada® (tenofovir and emtricitabine) in antiretroviral-naive adult patients. Efficacy data were collected over the first 48 weeks of the 96-week PROGRESS (PROtease/InteGRasE Simplification Study) study.

20 Jul 2010

Pharma industry leaders reduce R&D time, costs with aspenONE Process Development software

Aspen Technology, Inc., a leading provider of software and services to the process industries, today announced that GlaxoSmithKline, AstraZeneca and other pharmaceutical industry leaders are reducing their research and development time and costs using newly patented technology that is part of AspenTech's aspenONE Process Development for Pharmaceuticals software.

19 Jul 2010

Amira achieves two clinical development milestones in FLAP program for asthma

"Amira Pharmaceuticals, Inc. announced today that its FLAP (5-lipoxygenase-activating protein) program, which is partnered with GlaxoSmithKline, has achieved two clinical development milestones."

19 Jul 2010

Mylan declares quarterly dividend of $16.25 per share

Mylan Inc. today announced that in accordance with its 2.139 million preferred stock issuance, the company has declared its quarterly dividend of $16.25 per share (based on the annual dividend rate of 6.5% and a liquidation preference of $1,000.00 per share) payable on Aug. 16, 2010, to holders of preferred stock of record as of Aug. 1, 2010.

19 Jul 2010

Encorium CRO acquires Progenitor

Encorium Group, Inc., a full service multinational clinical research organization (CRO) conducting studies in over 30 countries for many of the world's leading pharmaceutical and biotechnology companies, today announced that it has acquired Progenitor Holdings AG, a corporation organized in Switzerland and its wholly-owned subsidiaries organized in Mexico, Panama, Argentina, Chile, Switzerland, India and Hong Kong for cash and stock valued at EURO 1.7 million, plus earn-out consideration of cash and stock with a value of up to EURO 1.5 million.

19 Jul 2010

Phase 2 CUBICIN study for prosthetic joint infections meets primary endpoint

Cubist Pharmaceuticals, Inc., a leading acute care therapeutics company, today announced that its Phase 2 safety study of CUBICIN (daptomycin for injection) in the treatment of prosthetic joint infections caused by certain Gram positive pathogens met its study objectives. This study was a first-of-its-kind randomized controlled Phase 2 trial studying anti-infective therapy in the setting of 2-stage surgery for the replacement of infected prosthetic hip or knee joints.

19 Jul 2010

U.S. District Court upholds validity of Nycomed's Protonix patent

Nycomed announced today that Judge Jose L. Linares of the U.S. District Court for the District of New Jersey has confirmed the jury verdict in favor of Nycomed and Pfizer Inc. The decision upholds the jury verdict issued on April 23, 2010, confirming that the patent is valid and rejecting allegations by the defendants that the patent was invalid as obvious and invalid for double patenting. Against KUDCo, the US generic drug business of the Schwarz Pharma Group, which did not at-risk launch, final Judgment was entered as a result of Judge Jose L. Linares' rulings.

19 Jul 2010

Phase II data on Genetic Immunity's DermaVir vaccine to be presented at XVIII International AIDS Conference

Genetic Immunity, a US/Hungarian biopharmaceutical company developing nanomedicine-based immunotherapies for HIV/AIDS and other chronic diseases, is releasing Phase II data on the Company's novel DermaVir therapeutic vaccine for HIV/AIDS during the XVIII International AIDS Conference this week in Vienna, Austria. DermaVir, the first dendritic cell-targeting topical HIV vaccine candidate, employs nanotechnology to induce multi-faceted and long-lived immune responses capable of eliminating HIV infected cells.

19 Jul 2010

ViroStatics to present VS411 Phase II dose-ranging trial data at International AIDS Conference in Vienna

ViroStatics, a US/Italian biopharmaceutical company developing innovative immunotherapies for HIV/AIDS and other chronic diseases, is releasing Phase II data from a randomized, dose-ranging trial of VS411, the Company's novel combination product for treating HIV/AIDS, during the XVII International AIDS Conference this week in Vienna, Austria.

19 Jul 2010

New Jersey District Court denies Teva's motion to overturn jury verdict in generic Protonix litigation

Teva Pharmaceutical Industries Ltd. announced today that the U.S. District Court for the District of New Jersey denied Teva's motion to overturn an April 23, 2010, jury verdict finding the patent in suit not invalid. The Court also denied Wyeth and Nycomed's request for FDA to reset the date of Teva's final approval to January 2011, based on the fact that Teva has patent defenses remaining at the District Court, including patent misuse.

17 Jul 2010

CCTP focuses on identifying, testing drugs for cancer stem cell treatment

Cancer and stem cell biology researchers at the University of Colorado are launching the nation's first program focused on identifying and testing drugs that target and destroy cells thought to be at the root of cancer-cancer stem cells (CSCs).The Cancer Stem Cell-Directed Clinical Trials Program (CCTP) is a collaboration between the University of Colorado Cancer Center and the Charles C. Gates Center for Regenerative Medicine and Stem Cell Biology, both located at the University of Colorado School of Medicine.

17 Jul 2010

DOJ-HHS Medicare Fraud Strike Force charges 94 people for $251 million in false claims

Ninety-four people have been charged for their alleged participation in schemes to collectively submit more than $251 million in false claims to the Medicare program in the continuing operation of the Medicare Fraud Strike Force in Miami; Baton Rouge, La.; Brooklyn, N.Y.; Detroit and Houston, announced Attorney General Eric Holder, Department of Health and Human Services (HHS) Secretary Kathleen Sebelius, FBI Director Robert Mueller and Daniel R. Levinson, Inspector General of HHS.

17 Jul 2010

BioRadar develops TransFMDV for Foot and Mouth Disease

BioRadar UK Ltd. predicted one year ago the current severe Foot and Mouth Disease (FMD) outbreaks after recording an increase of the Replikin Count (ref. 1) of the FMD Virus (FMDV) to its highest level in 52 years. Based on these findings, a new synthetic Replikins Trans-Strain FMD Vaccine, called TransFMDV(TM), has been developed and is now available. The announcement was made at the recent Biorbis Conference on Vaccine Production and Manufacturing in Amsterdam, the Netherlands. The conference was attended by major pharmaceutical company executives to examine how vaccine production could be accelerated in view of the problem last year of responding "too little, too late" to the H1N1 influenza pandemic.

17 Jul 2010

ICON opens purpose-built clinical pharmacology unit within CMFT campus

ICON plc,, a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced the official opening of a purpose-built clinical pharmacology unit within the Central Manchester University Hospitals Foundation Trust (CMFT) campus in Manchester, UK. Initial studies in the unit utilising translational medicine methodologies to expedite drug development projects began in June, and already 110 volunteers have participated in studies there.

17 Jul 2010

Pacific Shore releases clinical trial results for Burner Balm lip balm

Pacific Shore Holdings, Inc., today announced the release of the highly anticipated clinical trial results for Burner Balm lip balm. According to lead clinical investigator, Dr. David E. Toomey, who has orchestrated a multitude of clinical trials for some of the top pharmaceutical manufacturers in the United States, "Over a twelve week period, 120 study participants who were overweight participated in the study. The Burner Balm group lost an average of 7 to 9 pounds versus the placebo group who lost an average of 1.43 to 1.64 pounds in the 12 week period.

17 Jul 2010

HealthCare Appraisers opens new office in Wayne, Pennsylvania

HealthCare Appraisers, Inc. (HAI) announced today that the firm has opened a new office in the Philadelphia area. The new office, in Wayne, Pennsylvania, is part of HAI's continued office expansion to provide fair market value (FMV) analysis and valuation services to the healthcare and life sciences industries nationwide.

17 Jul 2010

NEOP receives stockholder approval to increase company shares to 205 milliion

Neoprobe Corporation (OTCBB: NEOP), a diversified developer of innovative oncology surgical and diagnostic products, announced at its 2010 Annual Meeting of Stockholders that it received the approval of its stockholders to increase the number of authorized shares of the Company from 155 million to 205 million. In addition, stockholders re-elected Neoprobe President and CEO David C. Bupp, and elected for the first time, Brendan A. Ford and Eric K. Rowinsky, M.D. as Directors of the Company for terms ending at the 2013 Annual Meeting. Stockholders also approved the appointment of BDO Seidman, LLP to act as the Company's independent registered public accounting firm for 2010.

17 Jul 2010

Simulations Plus third-quarter consolidated revenues increase 14.9% to record $3.1 million

Simulations Plus, Inc., a leading provider of simulation and modeling software for pharmaceutical discovery and development, today reported financial results for its third quarter of fiscal year 2010 ended May 31, 2010 (3QFY10).

17 Jul 2010

Lab-on-Bead technology helps researchers cut years from drug development

New research accepted by the Journal of Molecular Recognition confirms that a revolutionary technology developed at Wake Forest University will slash years off the time it takes to develop drugs - bringing vital new treatments to patients much more quickly.

16 Jul 2010

USFDA approves Sun Pharma's generic Flomax ANDA

Sun Pharmaceutical Industries Ltd. announced that USFDA has granted approval for its Abbreviated New Drug Application to market a generic version of Flomax ®, tamsulosin capsules.

16 Jul 2010

Pharmaceuticals News and Research

Abbott presents 48-week PROGRESS study results at 28th International AIDS Conference

Pharma industry leaders reduce R&D time, costs with aspenONE Process Development software

Amira achieves two clinical development milestones in FLAP program for asthma

Mylan declares quarterly dividend of $16.25 per share

Encorium CRO acquires Progenitor

Phase 2 CUBICIN study for prosthetic joint infections meets primary endpoint

U.S. District Court upholds validity of Nycomed's Protonix patent

Phase II data on Genetic Immunity's DermaVir vaccine to be presented at XVIII International AIDS Conference

ViroStatics to present VS411 Phase II dose-ranging trial data at International AIDS Conference in Vienna

New Jersey District Court denies Teva's motion to overturn jury verdict in generic Protonix litigation

CCTP focuses on identifying, testing drugs for cancer stem cell treatment

DOJ-HHS Medicare Fraud Strike Force charges 94 people for $251 million in false claims

BioRadar develops TransFMDV for Foot and Mouth Disease

ICON opens purpose-built clinical pharmacology unit within CMFT campus

Pacific Shore releases clinical trial results for Burner Balm lip balm

HealthCare Appraisers opens new office in Wayne, Pennsylvania

NEOP receives stockholder approval to increase company shares to 205 milliion

Simulations Plus third-quarter consolidated revenues increase 14.9% to record $3.1 million

Lab-on-Bead technology helps researchers cut years from drug development

USFDA approves Sun Pharma's generic Flomax ANDA

Ultimate guide to the essential tools for the characterization of proteins, polymers and nanoparticles eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence